| Literature DB >> 26976653 |
William J Griffiths1, Jonas Abdel-Khalik2, Peter J Crick2, Michael Ogundare2, Cedric H Shackleton3, Karin Tuschl4, Mei Kwun Kwok4, Brian W Bigger5, Andrew A Morris6, Akira Honda7, Libin Xu8, Ned A Porter8, Ingemar Björkhem9, Peter T Clayton4, Yuqin Wang10.
Abstract
Smith-Lemli-Opitz syndrome (SLOS) is a severe autosomal recessive disorder resulting from defects in the cholesterol synthesising enzyme 7-dehydrocholesterol reductase (Δ7-sterol reductase, DHCR7, EC 1.3.1.21) leading to a build-up of the cholesterol precursor 7-dehydrocholesterol (7-DHC) in tissues and blood plasma. Although the underling enzyme deficiency associated with SLOS is clear there are likely to be multiple mechanisms responsible for SLOS pathology. In an effort to learn more of the aetiology of SLOS we have analysed plasma from SLOS patients to search for metabolites derived from 7-DHC which may be responsible for some of the pathology. We have identified a novel hydroxy-8-dehydrocholesterol, which is either 24- or 25-hydroxy-8-dehydrocholesterol and also the known metabolites 26-hydroxy-8-dehydrocholesterol, 4-hydroxy-7-dehydrocholesterol, 3β,5α-dihydroxycholest-7-en-6-one and 7α,8α-epoxycholesterol. None of these metabolites are detected in control plasma at quantifiable levels (0.5ng/mL).Entities:
Keywords: 7-Dehydrocholesterol; 7-Dehydrocholesterol reductase; 8-Dehydrocholesterol; Liquid chromatography–; Oxysterol; Sterol; mass spectrometry
Mesh:
Substances:
Year: 2016 PMID: 26976653 PMCID: PMC5018427 DOI: 10.1016/j.jsbmb.2016.03.018
Source DB: PubMed Journal: J Steroid Biochem Mol Biol ISSN: 0960-0760 Impact factor: 4.292